Neuroptika

Neuroptika is a biotech company in South Korea, founded in 2018. It has raised $5.7M across 2 rounds.

See Neuroptika

Employees
1–10
Founded
2018
Business Model
B2B
Total Funding
$5.7M
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 3 investors for this company. The full record is or through the API.

About

Neuroptika is a clinical-stage biotechnology company developing novel regenerative and neuroprotective therapies for ophthalmic diseases, with a primary focus on retinal degeneration. The company's pipeline includes NRO-CMK targeting neurodegenerative glaucoma via AAV-delivered CaMKII gene therapy, NRO-VTN targeting drusen formation in dry AMD, and an undisclosed program for diabetic retinopathy. Neuroptika's approach addresses unmet needs in conditions affecting hundreds of millions of patients globally where current treatments cannot halt or reverse optic nerve and retinal damage. The company has completed Phase 2 clinical trials for its lead corneal nerve regeneration asset and holds exclusive licenses from Icahn School of Medicine at Mount Sinai and Sanford Burnham Prebys.

Summary

It lists 1–10 employees. It has raised $5.7M in total across 2 rounds. Investors include KB Investment, Company K Partners and Woori Venture Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
SeedSeed Round
$2.7M

Sign up to see all 2 events

Funding, valuations, and company events, with amounts and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Neuroptika on Indexed.vc
<a href="https://indexed.vc/companies/neuroptika"><img src="https://indexed.vc/api/badge/company/neuroptika" alt="Neuroptika on Indexed.vc" width="260" height="76" /></a>